To download Immunovaccine's most recent corporate presentation click here
To visit Immunovaccine's Document Library click here .
Access to the Document Library (www.deliveringbreakthroughs.com) is available to all current and potential investors and partners
Immunovaccine Inc. is followed by the analyst(s) listed below. Please note that any opinions, estimates or forecasts regarding Immunovaccine’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Immunovaccine Inc. or its management.
Paradigm Capital Inc.
Senior Analyst: Alan Ridgeway Tel: 416.361.9080
Paradigm Capital initated coverage Feb. 26, 2010
To access reports visit www.paradigmcapinc.com/research
Video courtesy of the Halifax Chamber of Commerce produced by Spider Video
Investor Reception - Presentation recorded December 14, 2010
To listen to the audiocast presentation by Dr. Marc Mansour please click on the MP3 play button below:
Immunovaccine (TSX-V: IMV) is a clinical stage biotechnology company developing infectious disease and therapeutic cancer vaccines for human health. The company continues to strengthen its vaccine pipeline through licensing and strategic partnering. With positive pre-clinical safety data and recent partnerships with LIAI, NIH, Defence Research & Development Canada, and NCI the value of their Depovax™ vaccine delivery system has been significantly enhanced.
For further information about Immunovaccine, please contact Jennifer Cameron, Director of Communications at (902) 492-1819.
